069620 — Daewoong Pharma Share News
0.000.00%
Last trade - 00:00- KR₩1tn
- KR₩2tn
- KR₩2tn
Brief: Daewoong Pharmaceutical Announces Success In Developing A New Antidiabetic Medication
Brief: Daewoong Pharma Reports Q3 Standalone Revenue Krw 301.5 Bln
Brief: Daewoong Pharmaceutical Announces U.S. FDA Clearance Of IND Application For DWP213388, First-In-Class Irreversible Oral Dual Acting Inhibitor For Autoimmune Diseases
Brief: Daewoong Receives First Korean US FDA Fast-Track For New Idiopathic Pulmonary Fibrosis Drug
Brief: Daewoong Pharma Begins Phase 2 trial for DWN12088
Brief: Daewoong Pharmaceutical Announced First-Quarter 2022 Results
Brief: Daewoong Pharma, HanAll Biopharma Invest in Turn Biotechnologies to Expand Growth Initiative
Avacta up on collaboration with China's Biocytogen to develop drug candidates
Brief: Daewoong Pharmaceutical Announces Successful Phase 3 Results For New Antidiabetic Drug's Triple Combination Therapy
Brief: Daewoong Releases Positive Phase 3 Topline Results For New Antidiabetic Drug
Brief: Daewoong Pharma Says QTRLY Sales Recorded KRW 290.6 Billion, Which Is Up 5%
Evolus Inc: Down on Q4 revenue miss, bigger net loss
Evolus boosts balance sheet ahead of Q4 results, shares rise
Brief: Daewoong Pharma Says Wins 385 Billion Won Drug Export Order From Chinese Firm
Media: AbbVie wins bid to block U.S. imports of a botox rival - Bloomberg News
S.Korea shares close at record high on chip, auto boost
S.Korea Daewoong Pharma eyes Phase II trials of coronavirus drug, shares jump
Brief: Daewoong Pharmaceutical Announces Publication Of Novel P-Cab Fexuprazan Phase 1 Bridging Study
Brief: Daewoong Pharma Partners with Tufts Medical Center